UK biotech could be bound for recovery, BIA report reveals

New information debuted by the UK’s BioIndustry Association (BIA) has hinted towards the betterment of the British biotech financing market, which an adept says could assistance displacement attraction distant from fundraising to absorption connected advancing R&D.

In the BIA’s Q1 2026 biotech financing report, the commercialized assemblage noted that the full equity financing raised by UK companies was £552m ($746m) – marking a 18% uptick from the £466m ($632m) raised successful Q4 2025.

Meanwhile, task superior (VC) raising besides saw a 17% boost, with British biotechs securing £516m ($699m) successful Q1 2026, comparted to £442m ($599m) successful Q4 2025. While the worth of VC funds successful Q1 didn’t eclipse the £924m ($1.25bn) full raised successful the aforesaid play successful 2025, determination was a broader organisation of superior crossed companies, with 25 businesses securing backing successful 2026 compared with 15 successful Q1 2025.

Of these fundings, rounds from Series B and beyond pulled successful the largest stock of the currency astatine £276m ($374m) crossed 3 deals – highlighting the continued capitalist appetite for mature assets. According to the BIA, this highlights the burgeoning inclination towards less ample financings by investors, who are alternatively focusing connected selective, smaller superior allocations.

Despite the mostly affirmative trends for UK biotech successful Q1, this has not extended to the nationalist markets. With follow-on financing totalling conscionable £36m and nary British companies going public, UK enactment has remained stagnant crossed the quarter.

While the BIA’s manager of argumentation and outer affairs, Martin Turner tells Pharmaceutical Technology determination is apt nary cut-and-dry mode to amended this situation, helium notes that aboriginal changes could hinge connected the Nasdaq IPO model opening up, arsenic good arsenic the inclination towards investors adapting to geopolitical uncertainty.

Though British biotechs are hesitant to spell public, determination has been immoderate steadfast M&A enactment crossed the country, with Eli Lilly buying UK-based slumber cause biotech, Centessa Pharmaceuticals, for $7.8bn successful April, portion Amgen scooped up oncology specialist, Dark Blue Therapeutics, for $840m successful January.

As per the BIA, these deals item the continued involvement successful British biotechs and their science, contempt the nationalist financing challenges faced by the sector.

In speech with Pharmaceutical Technology, Turner noted that a 2nd 4th of accrued fundraising and an betterment successful the dispersed of this concern allows executives to progressively displacement their absorption to the science.

“There are much absorption teams present successful a presumption to absorption connected progressing their R&D programmes alternatively than fundraising, which is bully for the maturation and occurrence of the assemblage successful 2026, and of people for patients waiting for caller treatments,” Turner said.